Pharmaceutical industry faces $500 billion patent cliff between 2026 and 2032
More than $500 billion in worldwide prescription drug sales are at risk from generic competition as major pharmaceutical patents expire between 2026 and 2032, according to Norstella forecasting data. The patent expirations will occur in waves rather than as a single cliff, with Korean biosimilar manufacturers among those positioning to capture market share.
